Granted Patent B2

US 12,721,816 · App. 18/672,320 · Granted Sep 1, 2026

Inventors: Lixiao Wang (Henderson, NV); Peter Barnett (Shakopee, MN)

Assignee: Tonic Medical, Inc.

A61K9/4816A61K9/4833A61K31/337A61K31/436A61M25/10A61M25/1029A61P1/00A61M2025/1031A61M2025/105A61M2210/105

Abstract

Claims (60)

1 . A drug-releasing coating comprising:

polymer-encapsulated drug particles comprising

a therapeutic agent;

one or more polymers that encapsulate the therapeutic agent; and

a first ionic or zwitterionic additive in the polymer-encapsulated drug particles;

wherein the first ionic or zwitterionic additive comprises 1,2-dihexanoyl-sn-glycero-3-phosphocholine, 1,2-diheptanoyl-sn-glycero-3-phosphocholine, 1,2-dioctanoyl-sn-glycero-3-phosphocholine, 1,2-dilauroyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, 1,2-dinonanoyl-sn-glycero-3-phosphocholine, 1,2-didecanoyl-sn-glycero-3-phosphocholine, 1,2-diundecanoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), or a combination thereof; and

a release matrix comprising a second ionic or zwitterionic additive, wherein the second ionic or zwitterionic additive comprises a mismatched charged lipid and/or phospholipid, wherein two acyl groups of the mismatched charged lipid or phospholipid comprise mis-matched acyl groups, and wherein the mis-matched acyl groups differ by length, degree of saturation, substituents thereon, substitution patterns thereon, or combinations thereof, wherein the release matrix comprises the polymer-encapsulated drug particles dispersed therein.

2 . The drug-releasing coating of claim 1 , wherein the one or more polymers are 30 wt % to 80 wt % of the polymer-encapsulated drug particles, the first ionic or zwitterionic additive is 0.5 wt % to 20 wt % of the polymer-encapsulated drug particles, and the polymer-encapsulated drug particles have a weight ratio of the first ionic or zwitterionic additive to the one or more polymers of 1:3 to 1:60.

3 . The drug-releasing coating of claim 1 , wherein the one or more polymers are 50 wt % to 70 wt % of the polymer-encapsulated drug particles, the first ionic or zwitterionic additive is 2 wt % to 10 wt % of the polymer-encapsulated drug particles, and the polymer-encapsulated drug particles have a weight ratio of the first ionic or zwitterionic additive to the one or more polymers of 1:5 to 1:30.

4 . The drug-releasing coating of claim 1 , wherein the one or more polymers comprise PLGA having a weight ratio of lactic acid to glycolic acid of 85:15.

5 . The drug-releasing coating of claim 1 , wherein the therapeutic agent is sirolimus.

6 . The drug-releasing coating of claim 1 , wherein the polymer-encapsulated drug particles comprise a largest dimension of equal to or greater than 0.2 microns and less than or equal to 30 microns, as determined using laser light refraction.

7 . The drug-releasing coating of claim 1 , wherein the polymer-encapsulated drug particles are 10 wt % to 80 wt % of the drug-releasing coating by dry measure.

8 . The drug-releasing coating of claim 1 , wherein the second ionic or zwitterionic additive has a different molecular structure from the first ionic or zwitterionic additive.

9 . The drug-releasing coating of claim 1 , wherein the second ionic or zwitterionic additive is chosen from 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine, 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-lauroyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC), 1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine, 1-lauroyl-2-hydroxy-sn-glycero-3-phosphocholine, 1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine, 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine, and a combination thereof.

10 . The drug-releasing coating of claim 1 , wherein the polymer is at least one polymer chosen from polylactic acid (PLA), polyglycolic acid (PGA), a polylactic acid/polyglycolic acid copolymer (PLGA), polydioxanone, polycaprolactone, polyphosphazene, collagen, gelatin, chitosan, glycosoaminoglycans, and copolymers thereof.

11 . The drug-releasing coating of claim 1 , wherein the mis-matched acyl groups have lengths of C6-C34.

12 . The drug-releasing coating of claim 1 , wherein the mis-matched acyl groups differ by length.

13 . The drug-releasing coating of claim 1 , wherein the second ionic or zwitterionic additive is 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC).

14 . The drug-releasing coating of claim 1 , wherein the therapeutic agent is chosen from paclitaxel, docetaxel, taxol, an mTOR inhibitor, rapamycin, sirolimus, zotarolimus, everolimus, tacrolimus, umirolimus, an analogue thereof, and a combination thereof.

15 . The drug-releasing coating of claim 1 , wherein the drug-releasing coating comprises one or more antioxidants.

16 . The drug-releasing coating of claim 15 , wherein the therapeutic agent comprises the one or more antioxidants.

17 . The drug-releasing coating of claim 15 , wherein the one or more antioxidants comprise butylated hydroxytoluene (BHT).

18 . The drug-releasing coating of claim 1 , wherein the drug-releasing coating is on a balloon catheter, a drug-coated catheter, a drug-eluting stent, a drug-eluting stent on a balloon, a drug-eluting stent on a drug-coated balloon, a stent on a drug-coated balloon, or a combination thereof.

19 . The drug-releasing coating of claim 1 , wherein the release matrix further comprises one or more of polycationic polymers, polyanionic polymers, fatty acids, polyarginine, an amino dextran, a polycation-containing cyclodextrin, an amino cyclodextrin or a derivative thereof, a histone, a protamine, cationized human serum albumin, an aminopolysaccharide, chitosan, a peptide, poly-L-lysine, poly-L-ornithine, poly(4-hydroxy-L-proline ester), a polyethylenimine, a polyallylamine, a polypropylenimine, a polyamidoamine dendrimer, a cationic polyoxazoline, a poly(beta-aminoester), a PEG-PEI copolymer, a PLGA-PEI copolymer, a positively charged gelatin, hydroxy-terminated poly(2-methyl-2-oxazoline), poly(2-ethyl-2-oxazoline), stearic acid-modified branched polyethylenimine, branched PEI-g-PEG, poly(1-vinylpyrrolidone-co-2-dimethylaminoethyl methacrylate), poly(1-vinylpyrrolidone)-graft-(1-triacontene), polylysine, poly(N,N-dimethylaminoethyl methacrylate), a cationic copolymer of dimethylaminoethyl methacrylate/butyl methacrylate/methyl methacrylate, an anionic copolymer of methacrylic acid/methyl methacrylate, a copolymer of ethyl acrylate/methyl methacrylate/methacrylic acid ester with quaternary ammonium groups, 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC), 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC), stearic acid, or a combination thereof.

20 . The drug-releasing coating of claim 1 , wherein the release matrix is a layer of the drug-releasing coating.

21 . A balloon catheter comprising:

an elongated balloon; and

a coating layer overlying an exterior surface of the balloon, the coating layer comprising the drug-releasing coating of claim 1 .

22 . A method of making the drug-releasing coating of claim 1 , the method comprising:

forming a suspension comprising the therapeutic agent, the polymer, and the first ionic or zwitterionic additive;

processing the suspension to reduce particle size of the suspension; and

adding an aqueous premix to the suspension to form the polymer-encapsulated drug particles in the suspension

adding the second ionic or zwitterionic additive to the suspension, and drying the suspension, to form the drug-releasing coating.

23 . A method of making the drug-releasing coating of claim 1 , the method comprising:

forming an organic premix comprising an organic solvent, the one or more polymers, the therapeutic agent, and the first ionic or zwitterionic additive;

forming an aqueous premix comprising water and a water-soluble polymer or surfactant;

adding an organic solvent to the aqueous premix;

combining the aqueous premix and the organic premix together;

agitating the combined aqueous premix and organic premix to form an emulsion comprising the polymer-encapsulated drug particles;

forming a first mixture comprising the polymer-encapsulated drug particles and an organic solvent;

forming a second mixture comprising the second ionic or zwitterionic additive and an organic solvent;

combining the first mixture and second mixture; and

drying the combined first mixture and second mixture, to form the drug-releasing coating.

24 . A method of making a balloon catheter, the method comprising:

applying the drug-releasing coating of claim 1 to an exterior of a balloon of a balloon catheter.

25 . A method for treatment of a body lumen, the method comprising:

inserting the balloon catheter of claim 21 into a target site in a body lumen;

inflating the balloon at the target site to contact the coating layer with walls of the body lumen at the location of the non-vascular stricture until the balloon achieves an inflated balloon diameter for an inflation period;

deflating the balloon after the inflation period; and

withdrawing the balloon catheter from the body lumen.

26 . The method of claim 25 , wherein the body lumen comprises a urethra, a prostatic urethra, or a ureter.

27 . The method of claim 25 , wherein the body lumen comprises an esophagus, a stomach, a small intestine, a large intestine, a colon, or a rectum.

28 . The method of claim 25 , wherein the body lumen comprises an airway.

29 . The method of claim 25 , wherein the method reduces occurrence of a stricture at the target site in the body lumen.

30 . A method for reducing occurrence of a stenosis or stricture in a vascular body lumen, the method comprising:

inserting the balloon catheter of claim 21 into a target site in a body lumen comprising the vascular stenosis or stricture;

inflating the balloon at the target site to contact the coating layer with walls of the body lumen at the location of the stenosis or stricture until the balloon achieves an inflated balloon diameter for an inflation period;

deflating the balloon after the inflation period; and

withdrawing the balloon catheter from the body lumen.

Assignments (2)

Continuity (5)

References Cited (400)